Fig. 2
From: Contribution of small airway inflammation to the development of COPD
Exhaled NO in COPD patients. (A) The tendency of exhaled NO in COPD development from smoking to COPD. (A-1) FeNO50, (A-2) FeNO200, (A-3) CaNOdual, and (A-4) FnNO; (B) The changes of exhaled NO in COPD according to FEV1. (B-1) FeNO50, (B-2) FeNO200, (B-3) CaNOdual, and (B-4) FnNO; (C) The tendency of exhaled NO in smoking. (C-1) Relationship between exhaled NO in different smoking quantity and (C-2) Relationship between exhaled NO in quit smoking time. *p) < 0.05, **p) < 0.01 COPD vs. smoker and control; ¶p) < 0.05, ¶¶p) < 0.01 COPD vs. emphysema; Ɨp) < 0.05, ƗƗp) < 0.01 COPD vs. chronic bronchitis; #p) < 0.05, ##p) < 0.01 emphysema vs. control; ‡p) < 0.05, ‡‡p) < 0.01 chronic bronchitis vs. control; †p) < 0.05, ††p) < 0.01 smoker vs. control. COPD, chronic obstructive pulmonary disease, FEV1, forced expiratory volume 1; NO, nitric oxide